MTOR and osteosarcoma: Mechanistically, TRIM17 promotes the ubiquitination and degradation of FTO protein, enhances PDK1 mRNA stability via N6-methyladenosine (m6A) modification, and subsequently promotes phosphorylation-dependent activation of the AKT/mTOR signaling pathway, thereby driving osteosarcoma malignancy.